0000899243-21-018115.txt : 20210504 0000899243-21-018115.hdr.sgml : 20210504 20210504163057 ACCESSION NUMBER: 0000899243-21-018115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210504 FILED AS OF DATE: 20210504 DATE AS OF CHANGE: 20210504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Longwood Fund III, L.P. CENTRAL INDEX KEY: 0001640546 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 21888999 BUSINESS ADDRESS: STREET 1: PRUDENTIAL TOWER STREET 2: SUITE 1555, 800 BOYLSTON ST. CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-351-2590 MAIL ADDRESS: STREET 1: PRUDENTIAL TOWER STREET 2: SUITE 1555, 800 BOYLSTON ST. CITY: BOSTON STATE: MA ZIP: 02199 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Longwood Fund III GP, LLC CENTRAL INDEX KEY: 0001762853 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 21889000 BUSINESS ADDRESS: STREET 1: 800 BOYLSTON ST, SUITE 1555 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 6173512590 MAIL ADDRESS: STREET 1: 800 BOYLSTON ST, SUITE 1555 CITY: BOSTON STATE: MA ZIP: 02199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc. CENTRAL INDEX KEY: 0001785530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823523180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1030 MASSACHUSETTS AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 617-952-0555 MAIL ADDRESS: STREET 1: 1030 MASSACHUSETTS AVENUE STREET 2: SUITE 210 CITY: CAMBRIDGE STATE: MA ZIP: 02138 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-05-04 1 0001785530 Werewolf Therapeutics, Inc. HOWL 0001762853 Longwood Fund III GP, LLC 800 BOYLSTON STREET SUITE 1555 BOSTON MA 02199 0 0 1 0 0001640546 Longwood Fund III, L.P. 800 BOYLSTON STREET SUITE 1555 BOSTON MA 02199 0 0 1 0 Common Stock 2021-05-04 4 C 0 1071127 A 1071127 I See footnote Common Stock 2021-05-04 4 C 0 355955 A 1427082 I See footnote Common Stock 2021-05-04 4 P 0 250000 16.00 A 1677082 I See footnote Series A Preferred Stock 2021-05-04 4 C 0 9285714 0.00 D Common Stock 1071127 0 I See footnote Series B Preferred Stock 2021-05-04 4 C 0 3085811 0.00 D Common Stock 355955 0 I See footnote On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. These securities are held of record by Longwood Fund III, L.P. ("Longwood III"). Longwood Fund III GP, LLC ("Longwood III GP") is the general partner of Longwood III. Voting, investment and dispositive decisions at Longwood III GP with respect to the securities held by Longwood III are made by an investment committee comprised of Christoph Westphal, Richard Aldrich and John Lawrence (collectively, the "IC Members"). Longwood III GP and each of the IC Members may be deemed to share voting, investment and dispositive power over the securities held by Longwood III and as a result may be deemed to have beneficial ownership over such securities. Longwood III GP and each of the IC Members disclaims beneficial ownership over the securities held by Longwood III, except to the extent of their respective pecuniary interests therein. On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. By: /s/ John Lawrence, Chief Financial Officer of Longwood Fund III GP, LLC 2021-05-04 By: /s/ John Lawrence, Chief Financial Officer of Longwood Fund III GP, LLC, the general partner of Longwood Fund III, L.P. 2021-05-04